Trial Profile
A Phase 1b/2 Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Oct 2012
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Varlitinib (Primary)
- Indications Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 05 Apr 2011 Actual end date (Feb 2011) added as reported by ClinicalTrials.gov.
- 05 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.